Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Q3 FY2026 Earnings Presentation
19 slides from Strides Pharma Science's earnings presentation, Jan 30, 2026
Slide 1: Stock exchange filing cover letter
January 30, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Symbol: STAR Dear Sirs, Sub: Earnings Presentation for the quarter and nine months ended
Slide 2: Q3FY26 Earnings Presentation
Q3FY26 Earnings Presentation January 30, 2026 Strides Pharma Science Limited 1
Slide 3: Safe Harbor
Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p
Slide 4: Highest Ever Quarterly EBITDA of ₹2,359m in Q3FY26
Strides Continues to Deliver Exceptional Performance With Highest Ever Quarterly EBITDA of ₹2,359m in Q3FY26 Q3FY26 Operational PAT at ₹1,282m and EPS at ₹13.9, Grew ~39% YoY Tepid Revenue Growth at 3.6%, Impacted by Low Offtake in Institutional Business and Flattish US Operations Compensated by Str
Slide 5: Strides Delivers Consistent Growth Across Key Metrics in 9MFY26
Strides Delivers Consistent Growth Across Key Metrics in 9MFY26 9MFY26 9MFY25 YoY Change Revenue (₹m) 35,352 33,749 YoY 4.7% Gross Margins (₹m) 21,127 18,939 11.6% Gross Margin (%) 59.8% 56.1% 370bps EBITDA (₹m) 6,856 5,849 17.2% EBITDA Margin (%) 19.4% 17.3% 210bps Operational PAT (₹m) 3,8
Slide 6: Consistent Growth in Absolute Gross Margin, EBITDA and PAT
Consistent Growth in Absolute Gross Margin, EBITDA and PAT Growth Across P&L Metrics Delivers a Highest Ever EBITDA performance at ₹2,359m Total Revenue (₹/$M) Gross Margin (₹M) EBITDA (₹M) Operational PAT (₹M) $137 $141 $131 $141 $136 ₹ 1,130 ₹ 1,140 ₹ 1,403 ₹ 1,282 ₹ 2,103 ₹ 2,179 ₹ 2,181 ₹ 2,316
Slide 7: Ex-US Market Registers a Strong Growth of 20% YoY
Ex-US Market Registers a Strong Growth of 20% YoY Ex-US Markets are on track to mirror the US Market over the next two years Revenue Composition (₹M) US Market (₹M) Ex-US Markets (₹M) Access Market* (₹M) 222, 2% YoY 0% ↔ YoY 20% YoY 70% ₹ 6,121 ₹ 6,105 ₹ 5,620 ₹ 4,665 Q3FY26 ₹ 1,450 5,620, 6,105
Slide 8: US Market
BS Strides US Market
Slide 9: US Market Q3FY26 Revenue at $70m, Remained Steady
US Market Q3FY26 Revenue at $70m, Remained Steady Despite New Entrants in Recent Launches Year-on-Year Comparison (₹/$M) Comments ▸ Q3FY26 revenues at $70m, remained steady despite new entrants in recent launches YoY 0% ↔ ▸ Launched 4 products in 9MFY26 $73 $70 ▸ Discontinued 8 products in 9MFY26 th
Slide 10: Ex-US Markets
BS Strides Ex-US Markets
Slide 11: Ex-US Market Revenue at $64m, Grew 20% YoY
Ex-US Markets Ex-US Market Revenue at $64m, Grew 20% YoY Growth driven by all key markets across Australia, UK and EU Year-on-Year Comparison (₹/$M) Comments Other Regulated Markets YoY 20% $56 $64 ▸ All regulated markets ex-US form part of the Other Regulated Markets ▸ Q3FY26 ORM Revenue at $47.6
Slide 12: Financial Performance
Financial Performance • Strong Financial Discipline Enabled Profitability and Cashflow Generation
Slide 13: Income Statement – Reported Strong PAT in Q3FY26
Income Statement – Reported Strong PAT in Q3FY26 Income statement (₹m) Particulars Q3FY26 Q3FY25 YoY Q2FY26 QoQ 9MFY26 9MFY25 YoY I. Revenue 11,946 11,537 3.6% 12,208 -2.1% 35,352 33,749 4.7% II. Material Costs 4,629 4,801 5,153 14,225 14,810 III. Gross Margin (I- II) 7,317 6,735 8.6% 7,056 3.7% 21,
Slide 14: Net Debt at ₹13,527m on Constant Currency
Net Debt at ₹13,527m on Constant Currency after Funding for ₹2,836m of Capex & Growth Initiatives Reported Net Debt of ₹14,358m post FX Impact of ₹831m Particulars (In ₹m) Mar’25 Dec’25 Finance cost (In ₹m) Q2FY26 Q3FY26 Working Capital Loans 11,364 9,363 Long Term Loans 6,593 6,055 Interest Cost on
Slide 15: Significant Improvement in the Balance Sheet Metrics
Strong Oversight and Governance Leading to Significant Improvement in the Balance Sheet Metrics Net Debt to Equity (x) Net Debt to EBITDA (x) Cash to Cash Cycle (Days) 1.0 3.5 129 124 117 0.6 0.5 1.9 1.6 FY24 FY25 Q3FY26 FY24 FY25 Q3FY26 FY24 FY25 Q3FY26 Current Ratio (x) RoCE (%) Fixed Asset Turnov
Slide 16: Corporate Updates
BS Strides Corporate Updates
Slide 17: Strengthening Leadership Team
Strengthening Leadership Team Peter Hardwick Nandini Matiyani Chief Executive Officer – North America Executive Vice President - Human Resources Peter brings 30+ years of global pharmaceutical leadership spanning Nandini brings over 20 years of experience in people strategy, sales, marketing, portfo
Slide 18: Q3FY26 Earnings Call Details
Q3FY26 Earnings Call Details invites you to interact with the senior management on Q3FY26 Performance Click here to pre-register and join without the operator Jan 30, 2026 4:30 pm IST / 11:00 am GMT / 7:00 am EDT / 7:00 pm HKT Join through an operator using dial in numbers Participants from the Mana
Slide 19: Strides Pharma Science Limited Corporate Office
Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corporate Office Strides House, Bannerghatta Road, Bengaluru - 560 076, India Tel.: +91 80 6784 0000/ 6784 0290 Email: Investor-Relations@strides.com Registered Office ‘Cyber One’, Unit No. 902, Sector 30A, Vashi, Navi Mumbai - 400 703 Tel.:
Strides Pharma Science — Q3 FY2026 Earnings Presentation on 6ix